MCK supply chain intelligence for McKesson Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
McKesson Corporation (MCK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
McKesson sits inside pharmaceutical distribution, healthcare logistics, specialty drug, medical supply, and retail pharmacy networks. ChainSifter tracks verified McKesson supplier and customer relationships.
Use this MCK supply chain page to review healthcare distribution relationships, source evidence, and related supplier or customer chain pages.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | 95% | Reciprocal relationship from CHRS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS gra… |
| ADCT | ADC Therapeutics SA | 92% | Reciprocal relationship from ADCT graph: Customers from which we derive more than 10% of our total product revenues for the three months ended March 31, 2026 and 2025 are as follows: Three Months End… |
| JAZZ | Jazz Pharmaceuticals plc | 92% | Reciprocal relationship from JAZZ graph: Reciprocal relationship from MCK graph: Reciprocal relationship from JAZZ graph: The following table presents a summary of the percentage of total revenues fr… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 90% | Reciprocal relationship from AMPH graph: al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxyprogesterone for Amphastar’s current produc… |
| GILD | Gilead Sciences, Inc. | 85% | Reciprocal relationship from GILD graph: Reciprocal relationship from MCK graph: Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many… |
| MGNX | MacroGenics, Inc. | 85% | Reciprocal relationship from MGNX graph: Reciprocal relationship from MCK graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from MCK graph: Reciprocal relationship from MGNX gra… |
| RIGL | Rigel Pharmaceuticals, Inc. | 85% | Reciprocal relationship from RIGL graph: onouncements For a discussion of recent accounting pronouncements, see “Note 1– Description of Business and Summary of Significant Accounting Policies”, in th… |
| SCLX | Scilex Holding Company | 85% | Reciprocal relationship from SCLX graph: Reciprocal relationship from MCK graph: Reciprocal relationship from SCLX graph: 5, LLC (“Cardinal Health 105”), ships them to temperature-controlled customer… |
| ARDX | Ardelyx, Inc. | 72% | Reciprocal relationship from ARDX graph: Reciprocal relationship from MCK graph: Reciprocal relationship from ARDX graph: Reciprocal relationship from MCK graph: Reciprocal relationship from ARDX gra… |
| CAH | Cardinal Health, Inc. | 72% | nternational, national, regional, and local full-line, short-line, and specialty distributors, service merchandisers, self-warehousing chain drug stores, manufacturers engaged in direct distribution,… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph: nternational, national, regional, and l… |
| CLH | Clean Harbors, Inc. | 72% | Reciprocal relationship from CLH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CLH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CLH graph:… |
| COR | Cencora, Inc. | 72% | Reciprocal relationship from COR graph: Reciprocal relationship from MCK graph: Reciprocal relationship from COR graph: Reciprocal relationship from MCK graph: Reciprocal relationship from COR graph:… |
| CRM | Salesforce, Inc. | 72% | Reciprocal relationship from CRM graph: en & Katz, where he practiced law from September 2006 to July 2023. Mr. Niles received his B.S., B.A. and B.S. in Finance, Economics and Decision & Information… |
| CTOR | Citius Oncology, Inc. | 72% | Reciprocal relationship from CTOR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers a… |
| CTXR | Citius Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CTXR graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CTXR graph: adds the risk of import restrictions, and adds the risk of political and envi… |
| CVS | CVS Health Corporation | 72% | Reciprocal relationship from CVS graph: Reciprocal relationship from MCK graph: venues and approximately % of total trade accounts receivable at March 31, 2025. Sales to the Company’s largest custome… |
| CVS | CVS Health Corporation | 72% | venues and approximately % of total trade accounts receivable at March 31, 2025. Sales to the Company’s largest customer, CVS Health Corporation (“CVS”), accounted for approximately % of its total co… |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S.… |
| GRDN | Guardian Pharmacy Services, Inc. | 72% | Reciprocal relationship from GRDN graph: a “distinct pharmacy setting” and requires payors to compensate designated long-term care pharmacies for the specific services they are required to provide LT… |
| HALO | Halozyme Therapeutics, Inc. | 72% | Reciprocal relationship from HALO graph: Contents Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information… |
| HLN | Haleon plc | 72% | Reciprocal relationship from HLN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HLN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HLN graph:… |
| HROW | Harrow, Inc. | 72% | Reciprocal relationship from HROW graph: uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the ava… |
| HSIC | Henry Schein, Inc. | 72% | Reciprocal relationship from HSIC graph: s, as well as several manufacturers, of dental and medical products, primarily on the basis of price, breadth of product line, e-commerce capabilities, custom… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from MCK graph: Reciprocal relationship from LLY graph: ng at medical meetings. In addition, we advertise certain products directly to … |
| LOW | Lowe's Companies, Inc. | 72% | Reciprocal relationship from LOW graph: Reciprocal relationship from MCK graph: Reciprocal relationship from LOW graph: e Home Depot, Inc. (a home improvement retailer), 2010 – 2012; Vice President, … |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: . Includes cumulative translation adjustments. Amount in 2025 includes the reversal of $ million for a Zerbaxa (ceftolozane and tazobactam) sales-based milesto… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Item 1A. "Risk Factors - Risks Related to Manufacturing and Supply" for further information. Among the conditions for marketing approval of a new drug or biol… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products t… |
| TEVA | Teva Pharmaceutical Industries Limited | 72% | Reciprocal relationship from TEVA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from TEVA gra… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CVS | CVS Health Corporation | 95% | venues and approximately % of total trade accounts receivable at March 31, 2025. Sales to the Company’s largest customer, CVS Health Corporation (“CVS”), accounted for approximately % of its total co… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $11,444,651,336 across 10 awards. 36C24026K1002 EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER; 36C24026K1001 EXPRESS REPORT:… |
| CVS | CVS Health Corporation | 92% | Reciprocal relationship from CVS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CVS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CVS graph:… |
| CVS-HEALTH-CORPORATION | CVS-HEALTH-CORPORATION | 92% | Sales to our largest customer, CVS Health Corporation ("CVS"), accounted for approximately 24% of our total consolidated revenues in fiscal 2026. |
| GRDN | Guardian Pharmacy Services, Inc. | 92% | Reciprocal relationship from GRDN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from GRDN graph: Our primary wholesale distributor relationships currently include Cardinal He… |
| GROUP-PURCHASING-ORGANIZATIONS | GROUP-PURCHASING-ORGANIZATIONS | 90% | During fiscal 2026, sales to our ten largest customers, including group purchasing organizations ("GPOs") accounted for approximately 73% of our total consolidated revenues. |
| APO-PA | Apollo Global Management, Inc. | 85% | nnounced a definitive agreement under which funds managed by affiliates of Apollo Global Management, Inc. (“Apollo Funds”) will acquire approximately 13% minority ownership interest in our Medical‑Su… |
| APO-PA | Apollo Global Management, Inc. | 85% | Reciprocal relationship from APO-PA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from APO-PA graph: Reciprocal relationship from MCK graph: nnounced a definitive agreement u… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMPH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from AMPH gra… |
| CAH | Cardinal Health, Inc. | 72% | nternational, national, regional, and local full-line, short-line, and specialty distributors, service merchandisers, self-warehousing chain drug stores, manufacturers engaged in direct distribution,… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CAH graph:… |
| COR | Cencora, Inc. | 72% | Reciprocal relationship from COR graph: . We will continue to invest in advanced information systems and automated warehouse technology. U.S. Healthcare Solutions has made significant investments in … |
| CTOR | Citius Oncology, Inc. | 72% | Reciprocal relationship from CTOR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers a… |
| CTXR | Citius Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CTXR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers a… |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S.… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced b… |
| HALO | Halozyme Therapeutics, Inc. | 72% | Reciprocal relationship from HALO graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HALO graph: Contents Sales, Marketing and Distribution We have two teams of sales special… |
| HCA | HCA Healthcare, Inc. | 72% | Reciprocal relationship from HCA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HCA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HCA graph:… |
| HCA | HCA Healthcare, Inc. | 72% | liabilities assumed: Current assets $ Intangible assets Other non-current assets Current liabilities ( ) Total identifiable net assets Goodwill Net assets acquired $ SCRI Oncology, LLC On October 31,… |
| HROW | Harrow, Inc. | 72% | Reciprocal relationship from HROW graph: uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the ava… |
| HSIC | Henry Schein, Inc. | 72% | Reciprocal relationship from HSIC graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HSIC graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HSIC gra… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products t… |
| CARE-DISTRIBUTION-JOINT-VENTURE-L-P-ONCOLOGY-THE | CARE-DISTRIBUTION-JOINT-VENTURE-L-P-ONCOLOGY-THE | 62% | Corporation, McKesson Specialty Distribution LLC, McKesson Specialty Care Distribution Joint Venture, L.P., Oncology Therapeutics Network Corporation, Oncology Therapeutics Network Joint Venture, L.P… |
| CHANGE-HEALTHCARE-INC | CHANGE-HEALTHCARE-INC | 62% | the tax-free nature of the Exit; the effectiveness of a registration statement to be filed with the SEC; the receipt of other governmental approvals; the finalization of the NewCo capital structure; … |
| CHANGE-HEALTHCARE-LLC | CHANGE-HEALTHCARE-LLC | 62% | the tax-free nature of the Exit; the effectiveness of a registration statement to be filed with the SEC; the receipt of other governmental approvals; the finalization of the NewCo capital structure; … |
| COMMUNITY-ONCOLOGY-REVITALIZATION-ENTERPRISE-VEN | COMMUNITY-ONCOLOGY-REVITALIZATION-ENTERPRISE-VEN | 62% | sets 742 Current liabilities 176 Non-current liabilities 87 Net identifiable assets 479 Goodwill 437 Net assets acquired $ 916 Community Oncology Revitalization Enterprise Ventures, LLC On June 2, 20… |
| CONTINUED-PRISM-VISION-HOLDINGS-LLC | CONTINUED-PRISM-VISION-HOLDINGS-LLC | 62% | red, and the liabilities assumed, based on their fair values as of the acquisition date. The fair values of the assets acquired and liabilities assumed are preliminary and may be subject to additiona… |
| CORPORATION-MCKESSON-SPECIALTY-DISTRIBUTION-LLC | CORPORATION-MCKESSON-SPECIALTY-DISTRIBUTION-LLC | 62% | Corporation, McKesson Specialty Distribution LLC, McKesson Specialty Care Distribution Joint Venture, L.P., Oncology Therapeutics Network Corporation, Oncology Therapeutics Network Joint Venture, L.P… |
| HEALTH-RESOURCES | HEALTH-RESOURCES | 62% | rtifications, when and if given, could be challenged, and that manufacturers may seek modifications to their service agreements. CMS waived the initial Q1 2026 reporting deadline that had been set fo… |
| MCKESSON-CORP | MCKESSON-CORP | 62% | Corporation, McKesson Specialty Distribution LLC, McKesson Specialty Care Distribution Joint Venture, L.P., Oncology Therapeutics Network Corporation, Oncology Therapeutics Network Joint Venture, L.P… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MCK-DEBT | Debt stack $7.3B | 90% | Market cache reports total debt of $7.3B. |
| MCK-DEBT-7294 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2016-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MCK-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 2034 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| ADCT | ADC Therapeutics SA | 100.00 | 1 | ['supplier'] |
| COR | Cencora, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DVLT | Datavault AI Inc. | 100.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 | |
| CTXR | Citius Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| VEEV | Veeva Systems Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| DEO | Diageo plc | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CLX | The Clorox Company | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 1 | ['supplier'] |
| CAH | Cardinal Health, Inc. | 100.00 | 1 | ['customer', 'supplier'] |